Fibriant B.V., Has Expanded The Existing Recombinant Fibrinogen License Agreement With Bioceros B.V. For Fibrinogen Concentrates Market
The increasing availability of fibrinogen products and rise in a number of bleeding disorders are major factors serving as a driver for the fibrinogen concentrates market. According to the Centers for Disease Control and Prevention, in the United States, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. Fibrinogen products are widely used to treat health problems associated with fibrinogen deficiencies. Fibrinogen is a glycoprotein that helps in the formation of blood clots. Thus increasing demand for fibrinogen concentrates for treating bleeding disorders in patients is significantly contributing to the growth of the fibrinogen concentrates market. North America is expected to lead the global fibrinogen concentrates market owing to the growing focus on the adoption of fibrinogen products in the region. For instance, in November 2019, Octapharma USA sponsored a scientific symposium, "Fibrinogen Supplementation in Surgical...